About the Role
Scendea is seeking a highly motivated individual to join our global team as a full-time Principal Consultant (CMC, small molecules experience). The ideal candidate will have a proven track record in CMC for small molecule drug development, with expertise in process development, scale-up, regulatory submissions, and the pre-approval life cycle management of small molecule products. This is a hybrid position, affiliated to either of our UK or Australia offices, with a requirement to work in the office a minimum of one day per month.
Cambridge, UK – 22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation and dose-confirmation clinical trial to evaluate the safety and efficacy of HLX-4310, an investigational oral combination of a class I selective HDAC inhibitor and an mTOR inhibitor, in adolescents and adults with relapsed, refractory sarcoma, with a focus on osteosarcoma.
Scendea is seeking a Business Support Administrator to join our UK team in a 12-month fixed-term position. The role is full-time, Monday to Friday during standard office hours, and will be based at our Bishop’s Stortford office, with an anticipated start date of September 2026. This position reports into the Business Support Manager.
The successful candidate will be a highly organised professional with experience in systems administration, strong multitasking abilities, and excellent attention to detail.
The Company
Leadership expansion reinforces ELRIG's commitment to delivering impactful drug discovery initiatives and driving community-wide collaboration
We recently hosted our Ask the Experts Live Q&A: From Preclinical to First-in-Human.
In this session, our experts explored the strategic decisions that shape early clinical success, covering key considerations for transitioning from preclinical development into first-in-human studies. Drawing on their extensive experience, they discussed common challenges, practical approaches to reducing development risk, and the critical decisions that can help keep programmes on track.
About AstraZeneca
AstraZeneca is a global, science-led, patient-focused biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines for some of the world’s most serious diseases. But we’re more than one of the world’s leading pharmaceutical companies. At AstraZeneca, we are pioneering new frontiers by identifying and treating patients earlier, working towards the aim of eliminating cancer as a cause of death.
Plurify is an early-stage, fast-moving biotech building platform technologies to help unlock the next generation of stem cell and gene therapies. Our work targets the most stubborn manufacturing bottlenecks - including the unwanted residual cells and plasmids left behind during cell and gene therapy production - with scalable, precisely targeted solutions. With several Innovate UK grants and strong private backing behind us, we're growing the team.
💡 THE OPPORTUNITY
By Philippa Clark, Director of Business Development, One Nucleus
Company Description
TTP is an employee-owned technology and product development consultancy, with a 40-year track record of partnering with ambitious clients to solve complex challenges and bring innovative, commercially successful solutions to market.
We invent, design, and manufacture impactful products and technologies across a wide range of industries – including healthcare, life science, energy, and communications – and at the intersection of engineering, physical science, and biology.